Canaan Partners
http://www.canaan.com/homeCanaan Partners is a venture capital firm that invests in early stage technology and healthcare companies. Since its founding in 1987, Canaan has invested in more than 250 companies including DoubleClick and Match.com.
View Older Stories View More Recent Stories
-
Form 13F-HR Canaan Partners VII LLC For: Jun 30
-
Aircall Launches Latest Integration with Kustomer CRM for Support Teams
-
Unchained Labs racks up another one, acquires Trinean!
-
Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics
-
Diabetes Data Platform Leader Glooko Raises $35 Million in Series C
-
Launching the Biden Cancer Initiative
-
FinTech Innovation Lab Celebrates Seventh Anniversary, Entrepreneurs Debut Breakthrough Technologies in Cybersecurity, Artificial Intelligence and Fraud Detection
-
Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference
-
Spyryx Biosciences to Present at the 2017 BIO International Convention
-
Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
-
Hyalex Orthopaedics Raises $16 Million Series A Financing and Appoints Chief Executive Officer
-
Genome Medical Launches Expert Network for Clinical Genetics
-
Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference
-
Iterum Secures $65 Million in Series B Financing
-
Arix Bioscience leads $65 million Series B investment round for Iterum
-
Spyryx Biosciences to Present at American Thoracic Society International Conference May 19- 24, 2017, Washington, DC
-
Top Brands Choose Talena: Award-winning Software Reaches Major Data Milestone
-
The American Journal of Respiratory and Critical Care Medicine Publishes Study of Spyryx Biosciences' SPX-101, A Novel ENaC-Targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport
-
Spyryx Biosciences Partners with Cystic Fibrosis Canada, Serves as Presenting Sponsor of the 16th Broken Arrow Conference May 4-6, Toronto, Ontario
-
Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery
-
Leanplum Reveals 120 Power Words That Boost Push Notification Engagement & Conversions
-
Talena Named to CRN's 2017 Big Data 100 List
-
Leanplum Ranked #3 on Bay Area Best Places to Work List
-
Onkos Surgicalâ„¢ Secures $17.6M in Series B Funding Led by Canaan Partners
-
Golub Capital's Late Stage Lending Group Provides Growth Financing To Switchfly, Inc.
-
Form 13F-HR Canaan Partners VII LLC For: Mar 31
-
Spyryx Biosciences Presents Data and Corporate Update at Two Recent Conferences in Support of Clinical Candidate for Cystic Fibrosis
-
IVP Promotes Roseanne Wincek to Principal
-
CytomX Therapeutics (CTMX) Names Marion McCourt to Board of Directors
-
Spyryx Biosciences to Present at the Needham Healthcare Conference Tuesday, April 4, 2017 New York, N.Y.
-
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
-
Antiva Biosciences Closes $22 Million Series C Financing
-
Leanplum Helps Marketers Increase App Engagement With New iOS 10.3 Features
-
Mynd Property Management Raises $5.1 Million in Series A1 Financing
-
Unifi Secures $17.5 Million in Series B Funding from Scale Venture Partners
-
OncoResponse Announces Final Closing of $22.5M Series A Financing Round
-
Spyryx Biosciences Marks Rare Disease Day With an Update on Clinical Trials for SPX-101
-
Arrakis Therapeutics Announces $38 Million Series A Financing to Target RNA with Small-Molecule Medicines and Names Michael Gilman Chairman and CEO
-
Heart This: Emoji Push Notifications Increase Mobile Marketing Engagement
-
BrightFunnel Appoints Ross Fubini to Board of Directors
-
Kustomer Partners with Talkdesk to Provide Integrated Call Center and Voice Functionality
-
Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
-
Rocketrip Closes 2016 with 300% Year Over Year Customer Growth
-
Pharma industry shuns Trump push for radical shift at FDA
-
Komprise Raises $12M Series B, Announces General Availability of Komprise Data Management Grid
-
PitchBook Adds 266,000 Financials of Emerging Private Companies to its App, PitchBook Mobile
-
Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017
-
Form 13F-HR Canaan Partners VII LLC For: Dec 31
-
Liftstream Study Reveals Biotech Company Boardroom Diversity Still Far from Reality
-
Finalists Announced for First Annual LendIt Industry Awards

